Cutaneous leishmaniasis is endemic in the tropics and neotropics. It is often referred to as a
group of diseases because of the varied spectrum of clinical manifestations, which range …

Governed by parasite and host factors and immunoinflammatory responses, the clinical
spectrum of leishmaniasis encompasses subclinical (inapparent), localised (skin lesions) …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

Tegumentary leishmaniasis, comprising the cutaneous and mucocutaneous forms, is
caused by at least 13 dermotropic species of protozoa of the genus Leishmania, most of …

Pentavalent antimonials are first-line drugs for the treatment of the cutaneous form of
American tegumentary leishmaniasis. Second-line drugs include amphotericin B and …

The causative species of cutaneous leishmaniasis determines the clinical features and
courses, and treatments. Intralesional or systemic antimonials are the gold standard for the …

Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases
of cutaneous leishmaniasis reported yearly worldwide. There has been a sharp increase in …

Abstract Background. Pentavalent antimonials (SbV) are the first-line chemotherapy for
American tegumentary leishmaniasis (ATL). There are, however, reports of the occurrence of …

Cutaneous and mucosal leishmaniasis, caused in South America by Leishmania
braziliensis, is difficult to cure by chemotherapy (primarily pentavalent antimonials [SbV]) …

Leishmaniasis, resulting from infection with the protozoan parasite Leishmania, consists of a
wide spectrum of clinical manifestations, from healing cutaneous lesions to fatal visceral …